{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T05:22:30Z","timestamp":1670908950614},"reference-count":56,"publisher":"Informa UK Limited","issue":"sup3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Leukemia & Lymphoma"],"published-print":{"date-parts":[[2003,11,1]]},"DOI":"10.1080\/10428190310001623739","type":"journal-article","created":{"date-parts":[[2003,12,30]],"date-time":"2003-12-30T16:59:00Z","timestamp":1072803540000},"page":"S77-S83","source":"Crossref","is-referenced-by-count":0,"title":["Indolent B-Cell Malignancies: Immune Recognition and Antiself"],"prefix":"10.1080","volume":"44","author":[{"given":"John G","family":"Gribben","sequence":"first","affiliation":[{"name":"Dana Farber Cancer Institute, Harvard Medical School, 44 Binney Avenue, Boston, MA, 02115, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2011,4,20]]},"reference":[{"key":"CIT0001","first-page":"90, 3266\u2014 3274","author":"Maloney D.G","year":"1997","journal-title":"Blood"},{"key":"CIT0002","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.8.2825"},{"key":"CIT0003","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.17.3135"},{"key":"CIT0004","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.1.268"},{"key":"CIT0005","first-page":"1259 \u2014 1266","volume":"96","author":"Kaminski M.S.","year":"2000","journal-title":"updated results and long-term follow-up of the University of Michigan experience\", Blood"},{"key":"CIT0006","first-page":"18, 1316\u2014 1323","author":"Vose J.M.","year":"2000","journal-title":"Journal of Clinical Oncology"},{"key":"CIT0007","first-page":"4, 2599 \u2014 2604","author":"Multani P.S","year":"1998","journal-title":"Clinical Cancer Research"},{"key":"CIT0008","unstructured":"Grossbard, ML., Niedzwiecki, D., Nadler, L.M., Fruchtman, S.M., Schuster, M., Pecora, A., et al. (1998) \"Anti-B4 blocked ricin (anti-B4bR) adjuvant therapy post autologous bone marrow transplant: a Phase III Intergroup study\", Proceedings of the American Society for Clinical Oncology, 17, 3a [abstract 8]."},{"key":"CIT0009","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V90.6.2188"},{"key":"CIT0010","doi-asserted-by":"crossref","unstructured":"Hainsworth, JD., Burris, H.A. III, Morrissey, L.H., Litchy, S., Scullin, D.C. Jr, Bearden, J.D. III, et al. (2001) \"Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma\", Proceedings of the American Society for Clinical Oncology, 20, 294a [abstract 1175].","DOI":"10.1200\/JCO.2002.08.674"},{"key":"CIT0011","unstructured":"Gutheil, J.C., Funicane, D., Rodriguez, R., Saleh, F., Stahler, S. and Royston, I. (2000) \"Phase II study of rituximab in patients with previously untreated low-grade or follicular non-Hodgkin's lym-phoma\", Proceedings of the American Society for Clinical Oncology, 19, 22a [abstract 79]."},{"key":"CIT0012","first-page":"101","volume":"97","author":"Colombat P.","year":"2001","journal-title":"clinical and molecular evaluation\", Blood"},{"key":"CIT0013","unstructured":"Czuczman, M.S., Grillo-Lopez, A.J., White, C.A., Saleh, M., Gordon, L.I., Lo Buglio, A.F., et al. (2001) \"Progression-free survival after 6 years (median) follow-up of the first clinical trial of rituximab\/CHOP chemoimmunotherapy\", Blood, 98, 601a [abstract 2519]."},{"key":"CIT0014","unstructured":"Czuczman, M.S., Fallon, A., Mohr, A., Stewart, C., Klippenstein, D., Lond, P., et al. (2001) \"Phase II study of rituximab plus fludarabine in patients with low-grade lymphoma: final report\", Blood, 98, 601a [abstract 2518]."},{"key":"CIT0015","unstructured":"Zinzani, P.L., on behalf of an Italian Cooperative Study Group on Lymphoma. (2001) \"A randomised trial of fludarabine and mitoxantrone plus rituximab versus CHOP plus rituximab as first-line treatment in patients with follicular lymphoma\", Blood, 98, 842a [abstract 35001."},{"key":"CIT0016","unstructured":"Hiddemann, W., Forstpointer, R., Fiedler, F., Gramatzki, M., Dorkin, B., Illiger, H.J., et al. for the GLSG (2001) \"The addition of rituximab to combination chemotherapy with fludarabine, cyclophosphamide, mitoxantrone (FCM) results in a significant increase of overall response as compared to FCM alone in patients with relapsed or refractory follicular (FCL) and mantle cell lymphomas (MCL): results of a prospective randomized compar-ison of the German Low Grade Study Group (GLSG)\", Blood, 98, 844a [abstract 3507]."},{"key":"CIT0017","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.19.3918"},{"key":"CIT0018","first-page":"20, 2453\u2014 2463","author":"Witzig T.E.","year":"2002","journal-title":"Journal of Clinical Oncology"},{"key":"CIT0019","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.10.3270"},{"key":"CIT0020","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.9.2934"},{"key":"CIT0021","doi-asserted-by":"crossref","unstructured":"Press, OM., Unger, J.M., Braziel, R.M., Maloney, D.G., Miller, T.P., LeBlanc, M., et al. (2003) \"A Phase II trial of CHOP chemotherapy followed by tositumomab\/iodine 1131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: Southwest Oncology Group protocol S9911\", Blood, May 8 [Epub ahead of print].","DOI":"10.1182\/blood-2003-01-0287"},{"key":"CIT0022","first-page":"1050\u2014 1055","volume":"84","author":"Ratanatharathorn V.","year":"1994","journal-title":"\"Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non-Hodgkin's lymphoma\", Blood"},{"key":"CIT0023","first-page":"649 \u2014 653","volume":"3","author":"Jones R.J.","year":"1991","journal-title":"\"Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation\", Blood"},{"key":"CIT0024","first-page":"209","volume":"71","author":"Vandenberghe P.","year":"1995","journal-title":"\"Graft-versus-leukemia and graft-versus-lymphoma effects of allogeneic bone marrow transplantation and of allogeneic donor leukocyte transfu-sions\", Annals of Hematology"},{"key":"CIT0025","doi-asserted-by":"publisher","DOI":"10.1084\/jem.178.5.1801"},{"key":"CIT0026","first-page":"257, 789 \u2014 792","author":"Lenschow D.J.","year":"1992","journal-title":"Science"},{"key":"CIT0027","first-page":"94, 8789 \u20148794","author":"Kirk A.D.","year":"1997","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"CIT0028","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199906033402202"},{"key":"CIT0029","first-page":"8200\u2014 8204","volume":"92","author":"Schultze J.L.","year":"1995","journal-title":"a conceptual model to improve their tumor immunogenicity\", Proceedings of the National Academy of Sciences of the United States of America"},{"key":"CIT0030","first-page":"1992","volume":"93","author":"Buhmann R.","year":"1999","journal-title":"stimulation of allogeneic versus autologous T cells generates different types of effector cells\", Blood"},{"key":"CIT0031","first-page":"2757","volume":"100","author":"Schultze J.L.","year":"1997","journal-title":"an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immu-notherapy\", Journal of Clinical Investigation"},{"key":"CIT0032","doi-asserted-by":"publisher","DOI":"10.1084\/jem.177.4.925"},{"key":"CIT0033","first-page":"153, 666 \u2014 674","author":"Yellin M.J.","year":"1994","journal-title":"Journal of Immunology"},{"key":"CIT0034","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2400598"},{"key":"CIT0035","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V90.11.4297"},{"key":"CIT0036","first-page":"49, 481 \u2014483","author":"Maliszewski C","year":"2001","journal-title":"Pathologie-Biologie"},{"key":"CIT0037","first-page":"129","volume":"1","author":"Timmerman J.M.","year":"2001","journal-title":"\"The history of the development of vaccines for the treatment of lymphoma\", Clinical Lymphoma"},{"key":"CIT0038","first-page":"2268 \u2014 2271","volume":"36","author":"Stevenson G.T","year":"1977","journal-title":"a therapeutic target\", Federation Proceedings"},{"key":"CIT0039","doi-asserted-by":"publisher","DOI":"10.1002\/eji.1830270435"},{"key":"CIT0040","first-page":"271 \u2014 310","volume":"4","author":"George A.J.T.","year":"1989","journal-title":"\"Prospects for the treatment of B cell tumors using idiotypic vaccination\", Interna-tional Reviews of Immunology"},{"key":"CIT0041","first-page":"1209 \u2014 1215","volume":"327","author":"Kwak LW.","year":"1992","journal-title":"\"Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors\", New England Journal of Medicine"},{"key":"CIT0042","first-page":"3129 \u2014 3135","volume":"89","author":"Hsu F.J.","year":"1997","journal-title":"\"Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma \u2014 long-term results of a clinical trial\", Blood"},{"key":"CIT0043","first-page":"1171\u2014 1177","volume":"5","author":"Bendandi M.","year":"1999","journal-title":"\"Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma\", Nature Medicine"},{"key":"CIT0044","first-page":"667 \u2014672","volume":"6","author":"Trojan A.","year":"2000","journal-title":"\"Immunoglobulin framework-derived peptides function as cytotoxic T-cell epitopes commonly expressed in B cell malignancies\", Nature Medicine"},{"key":"CIT0045","first-page":"1750 \u2014 1755","volume":"97","author":"Wen Y.J.","year":"2001","journal-title":"evidence for their capacity to lyse autologous primary tumor cells\", Blood"},{"key":"CIT0046","first-page":"1029\u2014 1036","volume":"145","author":"Campbell M.J.","year":"1990","journal-title":"humoral and cellular requirements for the full expression of antitumor immunity\", Journal of Immunology"},{"key":"CIT0047","first-page":"1342","volume":"95","author":"Osterroth F.","year":"2000","journal-title":"\"Stimulation of cytotoxic T cells against idiotype immunoglobulin of malignant lymphoma with protein-pulsed or idiotype-transduced dendritic cells\", Blood"},{"key":"CIT0048","first-page":"5586","volume":"153","author":"Sette A.","year":"1994","journal-title":"\"The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes\", Journal of Immunology"},{"key":"CIT0049","first-page":"3308","volume":"156","author":"van der Burg S.H.","year":"1996","journal-title":"\"Immunogenicity of peptides bound to MHC class I molecules depends of the MHC peptide complex stability\", Journal of Immunology"},{"key":"CIT0050","first-page":"485 \u2014492","volume":"10","author":"Savage PA.","year":"1999","journal-title":"\"A kinetic basis for T cell receptor repertoire selection during an immune response\", Immunity"},{"key":"CIT0051","first-page":"213","volume":"50","author":"Rammensee H.","year":"1999","journal-title":"database for MHC ligands and peptide motifs\", Immunogenetics"},{"key":"CIT0052","first-page":"1392\u2014 1397","volume":"147","author":"Muller D.","year":"1991","journal-title":"\"A single amino acid substitution in and MHC class I molecule allows heteroclitic recognition by lymphocytic choriomeningitis virus-specific cytotoxic T lymphocytes\", Journal of Immunology"},{"key":"CIT0053","first-page":"98, 2999 \u2014 3005","author":"Hang S.","year":"2001","journal-title":"Blood"},{"key":"CIT0054","first-page":"2123","volume":"100","author":"Krackhardt A.M.","year":"2002","journal-title":"\"Identification of tumor-associated antigens in chronic lymphocytic leukemia by SEREX\", Blood"},{"key":"CIT0055","first-page":"41, 297 \u2014 316","author":"Murray G.I.","year":"2001","journal-title":"Annual Review of Pharmacology and Toxicology"},{"key":"CIT0056","first-page":"3026","author":"Murray G.I.","year":"1997","journal-title":"Cancer Research"}],"container-title":["Leukemia & Lymphoma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/10428190310001623739","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,12]],"date-time":"2022-12-12T16:13:26Z","timestamp":1670861606000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/10428190310001623739"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,11,1]]},"references-count":56,"journal-issue":{"issue":"sup3","published-print":{"date-parts":[[2003,11,1]]}},"alternative-id":["10.1080\/10428190310001623739"],"URL":"https:\/\/doi.org\/10.1080\/10428190310001623739","relation":{},"ISSN":["1042-8194","1029-2403"],"issn-type":[{"value":"1042-8194","type":"print"},{"value":"1029-2403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,11,1]]}}}